The Annals of pharmacotherapy · 2026
Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Linenfelser Lauren, Lipari Melissa, Kale-Pradhan Pramodini
Аннотация
OBJECTIVE: To review the pharmacology, efficacy, and safety of subcutaneous depemokimab-ulaa as add-on therapy in the treatment of severe eosinophilic asthma.
DATA SOURCES: PubMed database, Embase, and ClinicalTrials.gov were searched using the following terms: depemokimab, depemokimab-ulaa, Exdensur, and GSK3511294.
STUDY SELECTION AND DATA EXTRACTION: Articles published in English between January 2020 and March 2026, related to pharmacology, safety, efficacy, and clinical trials, were reviewed. Four studies met inclusion criteria.
DATA SYNTHESIS: In phase 3 trials, SWIFT-1 and SWIFT-2, depemokimab-ulaa demonstrated comparable reductions in elevated blood eosinophil (EOS) counts when compared to other interleukin-5 (IL-5) targeting therapies in patients with severe eosinophilic asthma. The annualized exacerbation rates were 0.46 and 0.56 with depemokimab-ulaa vs 1.11 and 1.08 with placebo (P < .001), respectively. There were no differences in other outcomes that were studied. In the phase 3 NIMBLE trial, depemokimab-ulaa did not meet the noninferiority margin when patients were switched from other anti-IL-5 therapies. Depemokimab-ulaa maintained a favorable safety profile, with no serious adverse events or deaths considered to be related to the drug.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:When compared with other anti-IL-5 agents, depemokimab-ulaa might serve as an effective alternative option with its twice-yearly dosing offering a significant advantage potentially improving patient adherence and clinical outcomes.
CONCLUSION: Depemokimab-ulaa's twice-yearly dosing offers a convenient alternative to other anti-IL-5 therapies as add-on treatment for severe eosinophilic asthma.
DATA SOURCES: PubMed database, Embase, and ClinicalTrials.gov were searched using the following terms: depemokimab, depemokimab-ulaa, Exdensur, and GSK3511294.
STUDY SELECTION AND DATA EXTRACTION: Articles published in English between January 2020 and March 2026, related to pharmacology, safety, efficacy, and clinical trials, were reviewed. Four studies met inclusion criteria.
DATA SYNTHESIS: In phase 3 trials, SWIFT-1 and SWIFT-2, depemokimab-ulaa demonstrated comparable reductions in elevated blood eosinophil (EOS) counts when compared to other interleukin-5 (IL-5) targeting therapies in patients with severe eosinophilic asthma. The annualized exacerbation rates were 0.46 and 0.56 with depemokimab-ulaa vs 1.11 and 1.08 with placebo (P < .001), respectively. There were no differences in other outcomes that were studied. In the phase 3 NIMBLE trial, depemokimab-ulaa did not meet the noninferiority margin when patients were switched from other anti-IL-5 therapies. Depemokimab-ulaa maintained a favorable safety profile, with no serious adverse events or deaths considered to be related to the drug.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:When compared with other anti-IL-5 agents, depemokimab-ulaa might serve as an effective alternative option with its twice-yearly dosing offering a significant advantage potentially improving patient adherence and clinical outcomes.
CONCLUSION: Depemokimab-ulaa's twice-yearly dosing offers a convenient alternative to other anti-IL-5 therapies as add-on treatment for severe eosinophilic asthma.